Cargando…
Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole
Venetoclax requires a 75% dose reduction when coadministered with voriconazole. In a 10-year historical cohort of treatment with venetoclax, we did not observe a worse hematologic outcome in patients who received voriconazole prophylaxis versus those who did not. Subtherapeutic voriconazole levels a...
Autores principales: | Hall, Victoria G, Tang, Kenny, Kumar, Deepali, Rotstein, Coleman, Chow, Signy, Chan, Steven M, Husain, Shahid, Hosseini-Moghaddam, Seyed M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064263/ https://www.ncbi.nlm.nih.gov/pubmed/37008567 http://dx.doi.org/10.1093/ofid/ofad134 |
Ejemplares similares
-
Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin
por: Alhadab, Ali A., et al.
Publicado: (2020) -
Voriconazole-refractory fungal infection of phacoemulsification tunnel
por: Mittal, Vikas, et al.
Publicado: (2010) -
Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study
por: Kim, Sun Bean, et al.
Publicado: (2017) -
Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study
por: Suetsugu, Kimitaka, et al.
Publicado: (2021) -
Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole
por: Mafuru, Magesa, et al.
Publicado: (2021)